（文章来源：证券日报） 证券日报网讯 1月30日，亚虹医药发布公告称，公司预计2025年度实现营业收入约24，248.13万元到 29，097.76万元，同比增长20.30%到44.36%；归属于母公司所有者的净利润为-37，766.54万元到-45， 319.85万元。 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2026-004 江苏亚虹医药科技股份有限公司2025年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 江苏亚虹医药科技股份有限公司（以下简称"公司"）预计2025年度实现归属于母公司所有者的净利润 为-37,766.54万元到-45,319.85万元，与上年同期相比，净利润增加-6,913.51万元（亏损同比增长 18.00%）到639.80万元（亏损同比减少1.67%）。 （二）业绩预告情况 1、经财务部门初步测算，预计2025年度实现归属于母公司所有者的净利润为-37,766.54万元 到-45,319.85万元，与上年同期相比，净利润增加-6,913.51万元（亏损同比增长18.00%）到639.80万元 （亏损同比减少1.67%）。 2、预计公司2025年度归属于母公司所有者扣除非经常性损益后的净利润为-39,628.87万元到-47,554.65 万元，与上年同期相比，扣除非经常性损益后的净利润增加-6,659.17万元 ...

证券代码：688176 证券简称：亚虹医药 公告编号：2026-004 江苏亚虹医药科技股份有限公司 2025 年年度业绩预亏公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经财务部门初步测算，预计 2025 年度实现归属于母公司所有者的净利润 为-37,766.54 万元到-45,319.85 万元，与上年同期相比，净利润增加-6,913.51 万 元（亏损同比增长 18.00%）到 639.80 万元（亏损同比减少 1.67%）。 2、预计公司 2025 年度归属于母公司所有者扣除非经常性损益后的净利润为 -39,628.87 万元到-47,554.65 万元，与上年同期相比，扣除非经常性损益后的净 利润增加-6,659.17 万元（亏损同比增长 16.28%）到 1,266.61 万元（亏损同比减 少 3.10%）。 4、预计公司 2025 年度研发费用约 25, ...

| 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入(元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600276 恒瑞医药 | | 3.33 Z | 5.10% | -2.89 Z | -4.43% | -4421.19万 | -0.68% | | 000963 华东医药 | | 1.15 Z | 16.50% | -7275.41万 | -10.40% | -4271.00万 | -6.10% | | 000813 德展健康 | | 1.02亿 | 50.51% | -6009.16万 | -29.70% | -4212.39万 | -20.82% | | 300436 | 广生堂 | 1.01亿 | 5.29% | -2204.37万 | -1.16% | -7860.17万 | -4.13% | | 688382 益方生物 | | 3813.99万 | 13.10% | -337.73万 | -1.16% | -3476.26万 | -11.94% | | 600 ...

中国经济网北京1月29日讯 亚虹医药(688176.SH)今日收报13.15元，跌幅7.91%。目前该股股价处于 破发状态。 亚虹医药于2022年1月7日在上交所科创板上市，发行数量为1.1亿股，发行价格为22.98元/股，保荐 机构为中信证券股份有限公司，保荐代表人为杨沁、程杰。 亚虹医药上市首日开盘即破发，当日盘中最高价报20.00元，为上市以来最高价。 (责任编辑：关婧) 亚虹医药首次公开发行股票的费用总额为1.47亿元，其中中信证券获得承销费及保荐费1.30亿元。 亚虹医药的控股股东、实际控制人、董事长兼总经理是PAN KE，美国国籍。 亚虹医药首次公开发行股票募集资金总额为25.28亿元，扣除发行费用后募集资金净额为23.81亿 元。亚虹医药最终募集资金净额比原计划多3.11亿元。亚虹医药于2021年12月31日披露的招股说明书显 示，该公司拟募集资金20.70亿元，拟分别用于药品、医疗器械及配套用乳膏生产项目，新药研发项 目，营销网络建设项目，补充流动资金。 ...

证券日报网讯1月23日，亚虹医药在互动平台回答投资者提问时表示，国家药品监督管理局药品审评中 心(CDE)已完成APL-1702的技术评审，公司将加快推进其上市审评审批工作，以期尽快获得上市批准。 ...

1月22日，亚虹医药涨2.01%，成交额3.16亿元。两融数据显示，当日亚虹医药获融资买入额2860.35万 元，融资偿还3792.85万元，融资净买入-932.50万元。截至1月22日，亚虹医药融资融券余额合计2.38亿 元。 融资方面，亚虹医药当日融资买入2860.35万元。当前融资余额2.38亿元，占流通市值的3.98%，融资余 额超过近一年80%分位水平，处于高位。 资料显示，江苏亚虹医药科技股份有限公司位于上海市浦东新区东育路221弄前滩世贸中心(三期)B栋 19F，成立日期2010年3月16日，上市日期2022年1月7日，公司主营业务涉及创新药物的研发、生产和 销售。主营业务收入构成为：抗肿瘤类产品96.34%，其他3.66%。 截至9月30日，亚虹医药股东户数2.52万，较上期减少1.06%；人均流通股17294股，较上期增加 16.41%。2025年1月-9月，亚虹医药实现营业收入2.16亿元，同比增长55.74%；归母净利润-2.49亿元， 同比增长8.08%。 机构持仓方面，截止2025年9月30日，亚虹医药十大流通股东中，鹏华医药科技股票A（001230）位居 第七大流通股东，持股614 ...

Core Viewpoint - Jiangsu Yahui Pharmaceutical Technology Co., Ltd. has received approval for the Phase I clinical trial of its product APL-2401 in Australia, which targets FGFR2/3-driven advanced solid tumors, marking a significant step in its international clinical research efforts [2][3]. Group 1: Drug Information - The drug APL-2401, also known as ASN-8639 tablets, is a highly selective small molecule inhibitor targeting FGFR2/3, aimed at providing new treatment options for patients with advanced solid tumors such as urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors [3][4]. - APL-2401 demonstrates superior dual kinase inhibition activity compared to existing FGFR2 or FGFR3 selective inhibitors, showing enhanced tumor cell killing and modulation of the tumor microenvironment while significantly reducing side effects associated with FGFR1 and FGFR4 [4]. Group 2: Clinical Trial Approval - The clinical trial application for APL-2401 has already been approved by the National Medical Products Administration (NMPA) in China, and the company is actively advancing the product's international multi-center clinical research [2][5]. - The approval process for the clinical trial in Australia was expedited, with the application being processed in just 22 working days, making it one of the first projects to receive approval under the new policy aimed at optimizing the review and approval of innovative drugs [5]. Group 3: Market Impact - The recent approval for the Phase I clinical trial in Australia is not expected to have a significant impact on the company's short-term performance, as drug development is characterized by long cycles, multiple approval stages, and substantial investment [2][6].

Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

亚虹医药公告称，子公司Asieris Pharmaceuticals(Aus)Pty Ltd收到澳大利亚相关机构批准，产品APL - 2401（药物名ASN - 8639片）获在澳开展Ⅰ期临床试验许可并完成备案。APL - 2401是自主研发的 FGFR2/3双靶点小分子抑制剂，此前已获国家药监局临床试验批准。该产品有望为晚期实体瘤患者提供 新疗法，相比同类产品有潜在优势。不过，此次获批对近期业绩无重大影响，研发存在不确定性。 ...